Skip to main content

John Kuch

Equibles does not estimate personal net worth.

About John Kuch

Earlier roles on record: CFO at Xencor Inc (XNCR) until April 19, 2024 and CFO at Xencor Inc (XNCR) until March 31, 2024. Xencor Inc reported in an 8-K filed October 26, 2023 that John Kuch retired as Senior Vice President and Chief Financial Officer, effective March 31, 2024. The proxy statement of Xencor Inc reports total compensation of $4,287,528 for John Kuch in fiscal 2024, including a base salary of $143,591. Disclosed compensation is on record for 5 fiscal years. John Kuch has spoken on 14 earnings calls across 1 company, most recently for Xencor Inc on November 7, 2023. The companies whose calls John Kuch spoke on are classified in the Healthcare sector.

“On October 24, 2023, John Kuch, Senior Vice President and Chief Financial Officer, notified Xencor, Inc. (the "Company") of his intention to retire from the Company effective March 31, 2024.”
Xencor Inc Form 8-K, filed October 26, 2023 · Read the filing

John Kuch on recent calls

“There is – it’s two separate transactions. One is the Ultomiris deal, which there’s caps from $26 million to $28 million, the first $35 million OMERS, we get the excess over that.”
CFO, Xencor Inc Q3 FY2023 Earnings Call ·
“To address your question, it can be lumpy, the early-stage R&D. I mean, there are preclinical studies but it's not going to be consistently increased quarter-to-quarter to the extent that it was over the previous year.”
CFO, Xencor Inc Q1 FY2023 Earnings Call ·
“Xencor's broad portfolio of partnerships, collaborations, and licenses continues to generate strong cash flow to support our operations. In 2022, we received $198.7 million in royalties and milestone payments, which helped fund our investments in our portfolio of bispecific and cytokine drug candidates.”
CFO, Xencor Inc Q4 FY2022 Earnings Call ·
“Xencor's portfolio of collaborations and licenses with partners provides ongoing revenue streams to support investments in our research activities and our expanding pipeline of bispecific and cytokine candidates.”
CFO, Xencor Inc Q3 FY2022 Earnings Call ·
“Total revenue for the second quarter and the first six months of 2022 was $31 million and $115.6 million, respectively. Revenue for the second quarter and the first half of 2022 was primarily royalty revenue from Vir and Alexion partnerships, related sales of sotrovimab and ULTOMIRIS, respectively.”
CFO, Xencor Inc Q2 FY2022 Earnings Call ·

Affiliation history

Company network

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2024 Xencor Inc (XNCR) $143,591 $4,287,528
2023 Xencor Inc (XNCR) $468,000 $2,233,493
2022 Xencor Inc (XNCR) $450,000 $2,114,941
2021 Xencor Inc (XNCR) $415,000 $1,745,969
2020 Xencor Inc (XNCR) $400,000 $1,504,141

Recent activity